Clinical trials: malaria
Zika, Dengue
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Background: Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control.
- Conditions
- Zika, Dengue, Malaria, Chikungunya
- Trial name
- NCT03641339
- Testing
- One vector feeding, Four vector feeding
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Lymphatic Filariasis
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in…
- Trial name
- RIMDAMAL (NCT02509481)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 2,712 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Malaria
The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya
The purpose of this study is to determine whether folic acid, which is often routinely given to pregnant women to prevent birth defects and anemia, affects the efficacy of sulfadoxine-pyrimethamine, another drug that is routinely…
- Trial name
- NCT00130065
- Testing
- Sulfadoxine-pyrimethamine/folic acid
- Where
- Kenya
- Volunteers
- 600 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali
This study will determine the immune response to malaria infection in healthy volunteers compared with malaria patients. Malaria affects millions of people in Mali and Africa.
- Trial name
- NCT00471302
- Where
- Mali
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make…
- Trial name
- NCT00344539
- Testing
- AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
Significant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for Plasmodium falciparum than P. vivax. P.
- Trial name
- SCOPE (NCT05874271)
- Testing
- Revised case management package
- Where
- 4 sites in Papua New Guinea
- Volunteers
- 794 people
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
This clinical study will evaluate an investigational malaria vaccine called PvCS/Montanide ISA-51 to determine whether it is safe and whether it can protect adults from infection with Plasmodium vivax, one of the main parasites…
- Conditions
- Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention
- Trial name
- PvCS/M51 (NCT07373301)
- Testing
- PvCS/Montanide ISA-51 VG Vaccine
- Where
- Colombia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination
In the current study, three experimental approaches aiming at reducing malaria transmission will be tested. The study will cover two transmission season (2019 and 2020) and the interventions will vary by season.
- Trial name
- INDIE-1b (NCT04053907)
- Testing
- Community Case Management, Weekly fever screening and treatment, Monthly malaria screening
- Where
- The Gambia
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Mortality, Malaria
Improved Management and in-Hospital Mortality
The study intend to evaluate whether the use of standardised malaria case management protocol plus financial incentives added to the availability of free drugs reduce the case-fatality at the paediatric ward.
- Trial name
- MTV (NCT00465777)
- Testing
- Guideline adherence and financial incentive
- Where
- Guinea-Bissau
- Volunteers
- 950 people
- Sponsor
- Bandim Health Project
Malaria
Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes
Study designed to evaluate safety and tolerability of a genetically attenuated P. falciparum (GAP3KO) that arrests early in the liver stage of the parasite life cycle.
- Trial name
- NCT02313376
- Testing
- GAP3KO
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Intestinal Helminthiasis, Ascariasis
Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children
Many school children in Kenya are infected with plasmodia and helminth species and are at risk of coinfection. It has been suggested that the immune response evoked by helminth infections may modify immune responses to plasmodia…
- Conditions
- Intestinal Helminthiasis, Ascariasis, Hookworm, Malaria
- Trial name
- NCT01658774
- Testing
- Albendazole, Vitamin C
- Where
- Kenya
- Volunteers
- 2,377 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Repeat Ivermectin Mass Drug Administrations for MALaria Control II
RIMDAMAL II is a double-blind, cluster randomized trial in Burkina Faso designed to test whether repeated ivermectin mass drug administrations, integrated into a monthly delivery platform with standard malaria control measures of…
- Trial name
- RIMDAMAL II (NCT03967054)
- Testing
- Ivermectin
- Where
- Burkina Faso
- Volunteers
- 4,124 people, healthy volunteers welcome
- Sponsor
- Brian Foy
Uncomplicated Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.
- Trial name
- NCT00356005
- Testing
- azithromycin plus artesunate, Artesunate
- Where
- Bangladesh
- Volunteers
- 228 people
- Sponsor
- Medical University of Vienna
Plasmodium Infections
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short…
- Trial name
- NCT00330902
- Testing
- sulfadoxine-pyrimethamine (SP) plus artesunate (AS), primaquine (PQ) plus SP+AS
- Where
- Sudan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Antioxidant Micronutrients in Malaria
In the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in Africa. An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5…
- Trial name
- AMM (NCT01152931)
- Testing
- Amodiaquine + Artesunate, Lumefantrine + Artemether, Artesunate + vitamin A
- Where
- 2 sites in Nigeria
- Volunteers
- 10 people
- Sponsor
- University of Lagos, Nigeria
Malaria
Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers
The primary objective of this study is to compare the bioavailability of two formulations (tablets and granules for dispersion) of the antimalarial drug pyronaridine-artesunate [3:1] (Pyramax, PA) in healthy adults.
- Trial name
- NCT01868438
- Testing
- Pyronaridine-artesunate granules, Pyronaridine-artesunate tablets
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria
The main purpose of this study is to compare the drug levels of artesunate and sulfadoxine-pyrimethamine found in pregnant women with malaria to those drug levels found in non-pregnant women from other studies.
- Trial name
- NCT00331708
- Testing
- Artesunate plus sulfadoxine-pyrimethamine
- Where
- Mozambique
- Volunteers
- 3 people
- Sponsor
- Professor Karen I Barnes
Malaria,Falciparum, Parasitemia
Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
This is a single-centre, open-label, Phase Ib study designed to assess if intravenous injection of approximately 3200 P. falciparum (NF54 strain) sporozoites can be safely administered to achieve blood-stage parasitaemia with a…
- Conditions
- Malaria,Falciparum, Parasitemia, Protozoan Infections, Parasitic Disease
- Trial name
- NCT04310085
- Testing
- Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet, PfSPZ-DVI Challenge
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso
Background: Malaria is a disease that affects many people in Burkina Faso. It is caused by germs that are spread by mosquito bites. A vaccine that blocks the spread of malaria is important to get rid of the disease.
- Trial name
- NCT04650815
- Where
- 2 sites in Burkina Faso
- Volunteers
- 608 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.